跳至主要内容
临床试验/JPRN-UMIN000052764
JPRN-UMIN000052764尚未招募Unknown

Development of a biomarker for predicting the clinical effectiveness of tezepelumab in patients with severe asthma and elucidation of immunomodulatory effects of tezepelumab - Tokyo Asthma Study for Tezepelumab: TOAST2

Juntendo University School of Medicine0 个研究点目标入组 60 人开始时间: 2023年11月20日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Subjects with malignancy Current smokers and subjects with a history of smoking within the past 6 months Subjects receiving treatment with other biologics and less than 1 month since last administraion (benralizumab requires 2 months) Subjects who have received bronchial thermoplasty within the past 6 months Subjects with a history of anaphylaxis due to biologics Subjects currently pregnant or breastfeeding Subjects with chronic obstructive pulmonary disease with obvious emphysematous changes Subjects with hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, pulmonary hypertension, sequelae of tuberculosis, diffuse panbronchiolitis, and interstitial pneumonia

研究者

发起方
Juntendo University School of Medicine

相似试验